December 3, 2020 -- Abveris has entered into an antibody discovery partnership with Saccharo for the discovery of monoclonal antibodies to advance Saccharo's immuno-oncology therapeutic pipeline.
Under the agreement, Abveris will utilize its DiversimAb mouse model in combination with its next-generation B-cell screening platform (powered by Berkeley Lights Beacon) to rapidly discover monoclonal antibodies. In return for its services, Abveris will receive compensation partially in the form of equity.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
